



Metabolic and genetic derangement: a review of mechanisms involved in arsenic and lead toxicity and genotoxicity

Olubusayo Olujimi Sadiku¹ and Andrés Rodríguez-Seijo^{2,3,4}

¹ University of Lagos, College of Medicine, Faculty of Basic Medical Sciences, Department of Medical Laboratory Science, Lagos, Nigeria

² University of Porto, Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), Matosinhos, Portugal

³ University of Porto, Faculty of Sciences, Biology Department, Porto, Portugal

⁴ University of Vigo, Department of Plant Biology and Soil Sciences, Ourense, Spain

[Received in July 2022; Similarity Check in July 2022; Accepted in October 2022]

Urbanisation and industrialisation are on the rise all over the world. Environmental contaminants such as potentially toxic elements (PTEs) are directly linked with both phenomena. Two PTEs that raise greatest concern are arsenic (As) and lead (Pb) as soil and drinking water contaminants, whether they are naturally occurring or the consequence of human activities. Both elements are potential carcinogens. This paper reviews the mechanisms by which As and Pb impair metabolic processes and cause genetic damage in humans. Despite efforts to ban or limit their use, due to high persistence both continue to pose a risk to human health, which justifies the need for further toxicological research.

KEY WORDS: arsenic trioxide; DNA damage; human health; metal availability; oxidative stress; reactive oxygen species

Potentially toxic elements (PTE), such as lead (Pb), cadmium (Cd), arsenic (As), zinc (Zn), silver (Ag), chromium (Cr), and copper (Cu), occur naturally in metal-rich areas such as ultramafic or karst (1, 2). However, the major sources of exposure are anthropogenic as consequence of industrial and urban development, such as metal processing in mining, petroleum refining and combustion, smelting, other metal-based industrial operations (3, 4), production of chemical-based fertilisers (5), transportation (road and maritime traffic) (6), and even personal care products such as face cosmetics, skin lightening products, and herbal cosmetics (7). Rural areas are not spared, as long-range transboundary emissions can affect even the most remote regions (8, 9).

Humans are mainly exposed through inhalation, ingestion, and/or skin, and reports associate exposure with varying metabolic changes affecting the heart, kidney, liver, brain, developing foetus, and even the DNA (10–14). PTEs have also been associated with cancer, Parkinson's disease, and rare autoimmune disorder and/or degenerative diseases (15–17). They can also elicit genotoxic, cytotoxic, and carcinogenic effects (15, 16).

The aim of this paper is to review current knowledge about the sources of emission, human exposure, and mechanisms of toxicity and genotoxicity, as well as the carcinogenic potential of As and Pb, two elements that rank the highest on the Substance Priority List (SPL) issued by the Agency for Toxic Substances and Disease Registry (ATSDR) (18). Despite the efforts to ban or limit their use, both are highly persistent in the environment and continue to pose

a risk to human health, which justifies the need for further toxicological research.

ARSENIC

Arsenic is a metalloid that occurs naturally in soil and many kinds of rocks (19). It occurs in three major chemical forms. The most common organic As compounds are arsanilic acid ($C_6H_8AsNO_3$), methylarsonic acid (MMA) ($CH_3AsO_3H_2$), and dimethylarsinic acid (DMA) ($C_2H_7AsO_2$) (20–23). In addition to them, there are arsenolipids, predominantly present in fish and seafood. They appear in nine main structural groups, of which arseno-fatty acids (AsFAs) and arseno-hydrocarbons (AsHCs) are of particular interest due to their cytotoxicity, comparable to that of inorganic As (23). Inorganic compounds include arsenic trioxide (As_2O_3), sodium arsenate ($NaAsO_4$), lead arsenate ($PbHAsO_4$), arsenic trichloride ($AsCl_3$), calcium arsenate ($Ca_3(AsO_4)_2$), and arsine gas (AsH_3).

Arsenic has three ionised states: pentavalent arsenate (As^{V+}), trivalent arsenite (As^{III+}), and arsines (As^{III-}), and either of these states can be found in inorganic and organic forms. However, the trivalent or pentavalent states are the most common and mobile (24). The inorganic forms are generally considered more toxic, with trivalent arsenite being most toxic (22).

Humans are exposed to As through contaminated drinking water, medicines, cosmetics, or diet, as shown in Table 1. Upon

Table 1 Main sources and routes of exposure of As

Main sources	Sources	Route of exposure
Earth crust	Rocks (e.g., volcanic eruptions), naturally enriched areas (e.g., serpentine areas)	Ingestion/ Inhalation
Dietary sources	Seafood, contaminated water, accumulation in food crops, fruits and grains	Ingestion
Medicinal sources	Arsenic trioxide treatment for acute promyelocytic leukemia Arsenic-based drugs in veterinary medicine	Ingestion
Cosmetics	Skin lightening products and fairness creams	Intradermal
Industrial sources	Pesticide production, wood preservatives, microelectronics production, microwave devices, and lasers	Ingestion/inhalation
Air	Use of pesticides and agrochemicals, industrial sources	Inhalation

ingestion or inhalation, inorganic and organic As is readily absorbed in the gastrointestinal tract ($\geq 75\%$ for As^{III} , As^{V} , MMA, and DMA) or lungs, respectively (14). Arsine gas (AsH_3) is the most toxic form of As, and inhalation of over 32 mg/m³ is lethal after exposure of more than one hour. With inhalation of 80–160 mg/m³, death occurs in less than an hour, and with inhalation of >800 mg/m³ it is instantaneous (22, 25).

However, dermal absorption is less likely (26, 27). Whichever the route, absorbed As is mainly transported by the blood and deposited in the liver, kidney, lungs, skin, and, to a lesser extent, bones and muscles (28, 29). In the body, pentavalent arsenate is reduced to arsenite, which is further methylated in the liver into MMA^v and DMA^v, which are eliminated in urine and faeces (30, 31). Methylation was previously considered as a detoxification process, as both products are readily excreted by the kidneys. In contrast, recent studies have shown that methylated trivalent arsenite is as toxic, if not even more toxic, than their parent compound or inorganic forms (32–34).

The symptoms of As toxicity depend on the chemical form, exposure route and duration, and individual health. Acute As poisoning can result in nausea, vomiting, erythropenia, leukopenia, and a pricking sensation in the hands and legs. Skin lesions, systemic damage, nasal perforations, and vascular diseases are associated with long-term exposure (13). Chronic toxicity is known as arsenicosis. Chronic arsenicosis can facilitate the development of skin, lung, liver, and bladder cancer (35–37).

Mechanisms of toxicity

The mechanisms of As toxicity and genotoxicity in humans are not yet fully understood. Most toxicologically relevant data originate from *in vitro* studies. Important to note, As toxicity depends on its chemical form.

Arsenate and phosphate group

Arsenate (pentavalent) is a phosphate analogue with similar chemical structure and properties, which is why it replaces phosphate in several biological reactions. One reaction that has been studied *in vitro* (22) is glycolysis. In normal glycolysis, glucose is catabolised by phosphates to generate adenosine triphosphate (ATP) (38).

Arsenate, however, interrupts ATP generation through a mechanism called arsenolysis (22). During normal glycolysis, phosphate is linked enzymatically to D-glyceraldehyde-3-phosphate to form 1,3-bisphospho-D-glycerate. Arsenate may replace phosphate to form an unstable product 1-arsenato-3-phospho-D-glycerate, which is further hydrolysed into arsenate and 3-phosphoglycerate, bypassing the generation of ATP from 1,3-bisphospho-D-glycerate (22, 39). Arsenolysis may also occur during oxidative phosphorylation. In the mitochondria, ATP is synthesised from phosphate and adenosine diphosphate (ADP), but in the presence of arsenate, ADP-arsenate is formed instead (39, 40). The resulting decline in ATP generation can affect the normal functioning of cellular systems.

Arsenite and thiol groups

Arsenite (trivalent) can also diminish ATP generation via its reaction with thiol, that is, sulphhydryl, groups (-SH), which have a major role in the activity of certain enzymes, coenzymes, and receptors. Arsenite binding to critical thiol groups in such molecules can interfere with some biochemical reactions and result in cellular toxicity (29, 41). An example that has been studied *in vitro* is that of pyruvate dehydrogenase, an enzyme in the citric acid cycle. Arsenite's affinity for thiols, especially dithiols, alters the lipoic acid moiety and consequently inhibits pyruvate dehydrogenase activity (39, 40), which, in turn, can impair cellular respiration and reduce ATP generation (29, 42). Methylated trivalent arsenicals such as MMA³⁺ have been shown to be even more potent inhibitors of pyruvate dehydrogenase, GSH reductase, and thioredoxin reductase, all of which contain thiol groups (43). Inhibition of these enzymes can alter key redox reactions and may eventually lead to cytotoxicity or even cell death (41, 44).

Arsenic and oxidative stress

Another mechanism of As toxicity is the generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) that leads to oxidative stress in cells and can result in cellular damage and death (15, 45). Detectable levels of superoxide anion ($\text{O}_2^{\cdot-}$), hydrogen peroxide (H_2O_2), hydroxyl radical (OH \cdot), and nitric oxide (NO) have been found in human vascular smooth muscle cells (VSMC) (46,

47), human-hamster hybrid cells (48, 49) and vascular endothelial cells (28) exposed to As. Even at environmentally relevant concentrations or at non-lethal concentrations (below 5 $\mu\text{mol/L}$), As can still stimulate $\text{O}_2^{\cdot-}$ and H_2O_2 generation (50). In addition, it can also affect antioxidant enzymes (such as with GSH, see above) (51, 52).

Arsenolipids

Currently, only a few studies have assessed the potential risk of arsenolipids for human health. Arseno-hydrocarbons (AsHCs) are more toxic than arseno-fatty acids (AsFAs). Arsenolipids also lower the levels of cellular ATP (53–56). The mechanism is unclear but may be related to mitochondrial membrane damage and disrupted mitochondrial function. Studies with *Drosophila melanogaster* have shown that AsHCs can pass the blood-brain barrier (BBB) and affect development (54, 55). AsHCs can also enter the milk of lactating mothers after ingestion of fish. Exposure via breastmilk has been shown to affect neurodevelopment in infants and can be linked to the attention deficit hyperactivity disorder (ADHD) (53, 56).

Mechanism of genotoxicity

Various forms of As are genotoxic. Even methylated arsenicals, formerly thought to be harmless, can induce chromosome aberrations and are potent DNA-damaging agents (57). Arsenic and arsenic-containing compounds can activate or indirectly cause genetic changes or damage (58–60).

Potential mechanisms of As genotoxicity include ROS generation, chromosome aberrations (chromatid breaks and gaps), sister chromatid exchange, and the induction of micronucleated cells (61, 62). In recent studies, As has been linked to epigenetic modifications through key mechanisms of gene regulation and DNA methylation (63). ROS can react chemically with DNA resulting in the structural damage of chromosomes, which can further lead to cellular transformation and possibly to tumour proliferation (23, 64). Arsenic-induced chromosome aberrations originate from ROS-mediated single- or double-strand DNA breaks. The latter usually arise at sites where there are single-strand breaks nearby, on the opposite DNA strands, or due to endonuclease action (2, 33, 2, 65). If this happens at the late G1 phase or S phase (DNA synthesis) due to insufficient time for repair, chromatid-type or chromosome-type aberrations may occur in the subsequent metaphase (33). In a study by Kligerman et al. (66), MMA^{III} and DMA^{III} induced chromosome mutation in mouse lymphoma cells. Structural aberrations can also affect important regions on chromosomes, leading to various detrimental effects. Although the mechanism of alterations is not fully understood, aberrations in the expression of growth control genes are a key step toward carcinogenesis.

Inorganic As has been shown to modulate the expression of transcription factors – proteins controlling the transcription of genetic information from DNA to mRNA – by causing oxidative

stress through intracellular redox reactions (17, 67). In response to oxidative stress, certain early response genes are activated to protect against and prevent further damage. The major pathways involved in arsenic-induced ROS are nuclear factor kappa B (NF- κ B), tumour suppressor protein (p53) activating protein-1 (AP-1), Nrf2-antioxidant response element (ARE) signalling pathway, microRNAs (miRNAs), mitophagy pathway, tyrosine phosphorylation system, and mitogen-activated protein kinases (MAPKs) (1, 32, 68). Both NF- κ B and AP-1 are stress-response transcription factors that regulate the expression of genes involved in cellular antioxidant defence.

At low concentrations and shorter exposure periods, arsenite has been shown to induce both of these transcription factors in normal cells (69, 70).

NF- κ B dimers are normally present in the cytoplasm of unstimulated cells, but are inactive due to interaction with specific inhibitors (71). Production of ROS at As levels ranging from 1 to 10 $\mu\text{mol/L}$ stimulates NF- κ B (32). Concentrations above 10 $\mu\text{mol/L}$ induce phosphorylation and degradation of NF- κ B inhibitors, leading to the release of NF- κ B dimers, which then move to the nucleus and induce transcription of target genes (31, 72, 73). Some reports (72, 74) suggest that arsenite can interfere with the DNA binding of NF- κ B, although this was observed at physiologically non-relevant concentrations. AP-1, on the other hand, is maintained within the nucleus and is composed of homodimers or heterodimers of Jun and Fos proteins (32). Trivalent methylated arsenicals are potent inducers of AP-1-dependent gene transcription and its regulator proteins (75). Transactivation of AP-1 is achieved through phosphorylation of its activation domain by c-Jun N-terminal kinase (JNK) (75).

The ARE pathway protects cells from oxidative damage thanks to the Nrf2-induced expression of cytoprotective genes. Nrf2 is regulated by its repressor, kelch-like epichlorohydrin-associated protein 1 (Keap1) (76, 77). In the presence of excess reactive species, cysteine residues in Keap1 are s-alkylated and Nrf2 accumulates and translocates to the nucleus, where it binds to the ARE motif in the promoter region of target genes and antioxidant enzymes (32). Arsenite can impair Nrf2 ubiquitination and activate the Nrf2-induced antioxidant signalling pathway (77). The Nrf2 pathway may play a dual role in As toxicity, depending on the dose, exposure time, and cell types. Exposure of human skin fibroblasts to As_2O_3 at concentrations ranging from 0 to 10 $\mu\text{mol/L}$ for 24 h upregulated the expression of Nrf2 and its downstream target gene HO-1, which resulted with reduced levels of ROS (78). In human choriocarcinoma JAr cells, As increased oxidative stress with the production of H_2O_2 , leading to an increase in Nrf2/small Maf DNA binding activity and HO-1 expression (79). Similar results have been observed in mouse lymphatic endothelial cells (80).

In addition, As may induce epigenetic modifications by altering DNA methylation. The cell uses DNA methylation as an epigenetic mechanism to control gene expression. Thus, genes can either be expressed or repressed depending on the type of regulatory element

in which methylation occurs. Arsenic can either induce hypomethylation or hypermethylation, with the former being more common (81).

Methylation of arsenite is necessary for its excretion. However, methyl groups are also required for normal function of DNA methyltransferases (81, 82). Demanelis et al. (63) described two mechanisms of how As impairs DNA methylation: by lowering the expression of DNA methyltransferases 3 and DNA methyltransferases 1 (83–85) and by depleting methyl groups as it is being metabolised and making them unavailable for DNA methyltransferases and DNA methylation.

Genotoxicity of As is a useful property in some cases, for example in antitumor therapy. Arsenic trioxide (As_2O_3) has shown some potential in the treatment of hypertrophic scars (78). Li et al. (86) reported that varying concentrations of As_2O_3 significantly inhibited cell proliferation, activation of caspase-3 (mediator of cell death), and JNk activation (86) in hepatocellular carcinoma (HepG2) cells. Antiproliferative effects of As on hepatocellular carcinoma have been studied extensively over the years and reported in several papers (87–89). However, recent findings by Chen et al. (90) suggest that hypoxic hepatocellular carcinoma cells develop resistance against As_2O_3 due to upregulation of the transcription factor HIF-1 α . Similar antitumor effects of As_2O_3 have been observed in glioma cells, in which As exerts anti-tumour effects via apoptosis and autophagy (91–93). While this is promising, the use of As for treatment calls for great caution, because normal cells respond differently to As exposure, and further studies are needed to ensure high target specificity and eliminate adverse effects.

Mechanism of carcinogenicity

The International Agency for Research on Cancer (IARC) classifies inorganic As as a group I carcinogen (63). Potential mechanisms of As carcinogenicity include genotoxicity, tumour production, co-carcinogenesis, cell proliferation, altered DNA

methylation, ROS production and oxidative stress (94), and production of dimethyl arsenate (DMAv), which at extremely high concentrations is carcinogenic in rat bladder (95, 96).

LEAD

Lead (Pb) is a widely used element due to its softness, malleability, ductility, poor conductivity, and resistance to corrosion. Its extensive use has brought about human exposure in various ways, mainly through environmental pollution. For many years now, it has been banned in petrol, paint, and several other applications, but being a non-biodegradable element, it persists in the environment, and is easily accumulated in all ecosystems. Pb is highly toxic (4, 97, 98), especially for the nervous system development in children. In 2017, the Institute for Health Metrics and Evaluation (IHME) estimated that Pb exposure accounted for 1.06 million deaths and 24.4 million disability-adjusted life years (DALYs) worldwide due to long-term effects on health (99). Table 2 shows the main sources and routes of human exposure.

Ingestion and inhalation dominate, while absorption through the skin is minimal and mostly concerns organic tetraethylated and tetramethylated Pb. When Pb-contaminated food, water, or soil is ingested, it is easily absorbed by the digestive system (100). When inhaled from polluted air, it is directly absorbed through the lungs (smaller particles) or cleared by the mucociliary transport (larger particles) only to be swallowed and absorbed in the gastrointestinal tract (28).

Absorbed Pb is transported by the blood to soft (e.g., liver, kidney, brain, spleen, ovary, and prostate) and mineralising (bone, teeth) tissues. Its elimination takes about 30–40 days from the first and about 10–20 years from the second (99, 100).

Lead has no physiological function in the human body but impairs multiple biochemical processes, and affects the renal, reproductive, and nervous (especially in children) systems (101, 102).

Table 2 Main sources and route of exposure of Pb

Main sources	Sources	Route of exposure
Earth crust	Naturally enriched areas (e.g., black shale areas)	Ingestion and dermal contact
Dietary sources	Contaminated food, lead accumulated in plants (e.g., urban agriculture), game hunting meat	Ingestion
Medicinal sources	Some traditional medicines	Ingestion
Cosmetics	Lipstick, Nail polish	Intradermal (organic forms only)
Industrial sources	Lead-based paints, mining and smelting, lead acid battery production, solder and glassware production, recycling activities	Ingestion/Inhalation
Recreational activities	Use of indoor firearms, recreational shooting activities and/or fishing activities	Inhalation, dermal contact, ingestion
Air	Combustion of lead-based gasoline, tobacco smoke, leaded aviation fuel	Inhalation
Drinking water	Lead pipes	Ingestion
Soil	Contaminated soil	Ingestion (mainly in children)

Until 2012, having a blood Pb level of 10 µg/dL or above was considered “level of concern” in children. Since 2012, the US Centers for Disease Control has lowered this threshold to 5 µg/dL (103–105). This reference value was then also adopted for adults by the National Institute for Occupational Safety and Health (NIOSH) in 2015 (106). According to the World Health Organization (WHO), there is no safe blood Pb concentration. Flannery and Middleton (107) have recently published an extensive report regarding blood Pb levels in children and adverse effects associated with reference values. Table 3 summarises symptoms of Pb toxicity, depending on its concentration in blood.

Mechanisms of toxicity

The mechanisms of Pb toxicity include oxidative imbalance (that could lead to oxidative stress), interference with enzymes, and various phenomena at the molecular level, including single nucleotide polymorphisms and epigenetic modifications, while recent studies also report changes in regulatory RNA or microRNA (miRNA) molecules (108, 109). Oxidative stress, however, is considered the major mechanism of Pb-induced toxicity.

Lead and oxidative stress

Lead induces oxidative stress via the generation of ROS [such as superoxides (HO₂·), singlet oxygen, and hydrogen peroxide (H₂O₂)] and depletion of intrinsic antioxidants that counter ROS (110–112).

Pb leads to the generation of ROS mostly by inhibiting δ-aminolevulinic acid dehydratase, which catalyses porphobilinogen (PBG) formation (113, 114). This, in turn, results in the accumulation of δ-aminolevulinic acid (ALA) through the negative feedback loop. ALA is a potent neurotoxin associated with neurological damage and the inhibition of Na⁺, K⁺-ATPase, and adenylate cyclase activities (115, 116). Increased ALA levels generate free ROS, especially H₂O₂ and superoxide radicals. These radicals cause lipid

peroxidation and, by interaction with oxyhaemoglobin, they contribute to further generation of hydroxyl radicals (117). These, in turn, oxidise haemoglobin and impair oxygen transport to tissues. Hydroxyl radicals can also trigger red blood cell lysis (117).

Lead and thiol groups

Under normal circumstances, intrinsic antioxidants rise to mitigate ROS effects (118, 119). However, Pb can impair glutathione, one of the body’s main antioxidants, as it binds covalently with the thiol group in glutathione, glutathione reductase (GR), glutathione peroxidase (GPX), and glutathione-S-transferase (110, 119). A similar mechanism has been reported for other antioxidant enzymes such as catalase (CAT) and superoxide dismutase (SOD) (120). Along with inactivating these enzymes through covalent binding, Pb replaces zinc ions, which are important cofactors for their activity (110, 121).

In this sense, SOD, GPX, and CAT levels inversely correlate with increased blood Pb levels (122). For example, Kshirsagar et al. (123) reported that a 458 % increase in blood Pb (p<0.001) in occupationally exposed individuals was accompanied by a 50.4 % decrease in SOD (p<0.001) and a 34.33 % decrease in CAT (p<0.001) levels compared to non-exposed individuals.

Another enzyme whose activity is impaired by Pb is glucose-6-phosphate dehydrogenase (G6PD), which also contains numerous thiol groups. It supplies cells with nicotinamide adenine dinucleotide phosphate (NADP). Its reduced form, NADPH, serves as a donor of reducing equivalents in the antioxidant system. Since red blood cells lack other NADPH-producing enzymes, their survival depends on NADPH supplied by G6PD. Animal studies report varying effects of Pb on G6PD but all point to three possible and concurrent mechanisms of action. The first involves higher demand for NADPH and, ultimately, higher G6PD activity in red blood cells in response to increased ROS (124, 125). The second involves G6PD inhibition due to a formation of a Pb and thiol group complexes in the enzyme (126, 127). This, however, is more likely to occur *in*

Table 3 Symptoms of Pb toxicity at different blood lead concentrations [adapted from Rehman et al. (103)]

Acute Toxicity	Mild toxicity (40–60 µg/dL)	Moderate toxicity (60–100 µg/dL)	Severe toxicity (>100 µg/dL)
Metallic taste	Myalgia	Arthralgia (especially nocturnal)	Lead palsy (wrist or foot drop)
Abdominal pain	Paraesthesia	Muscular exhaustibility	A bluish black lead line on gums (Barton's line)
Constipation or diarrhoea	Fatigue	Tremor	Lead colic (intermittent severe abdominal cramps)
Vomiting	Irritability	Headache	Lead encephalopathy
Hyperactivity or lethargy	Abdominal discomfort	Diffuse abdominal pain	
Ataxia		Anorexia, metallic taste, vomiting	
Behavioural changes		Constipation	
Convulsions and coma		Weight loss	
		Hypertension	

vitro than *in vivo*. The third involves glutathione depletion, which in turn increases the demand for NADPH (121, 128).

Altogether, Pb exposure may both increase or decrease G6PD activity, depending on concentration, duration of exposure, and the integrity of the cellular antioxidant system (118, 129).

Lead and ions

Another significant mechanism of Pb toxicity is substitution of divalent cations vital for biological processes like Ca^{2+} , Mg^{2+} , Fe^{2+} , Zn^{2+} and monovalent cations like Na^+ (110, 121). Pb^{2+} , for example, can replace Ca^{2+} at binding sites and activate or inhibit them, depending on its level (121, 130). This effect is the most prominent in the nervous system. After replacing Ca^{2+} , Pb can cross the BBB and accumulate in astroglial cells (110, 121). The neurotoxic effect on immature astroglial cells is particularly pronounced, as they play an important role in the development of BBB (131).

Mechanism of genotoxicity

Several studies using different Pb-containing compounds in various biological systems have provided evidence of direct or indirect interaction between Pb and genetic material. Genotoxic effects observed *in vitro* and in animal and human studies range from the production of free radicals, inhibition of DNA repair to DNA double-strand breaks, chromosome aberrations, sister chromatid exchange (SCE), and increased micronucleus (MN) frequency (132, 133).

Recent studies have linked increased Pb levels to chromosome aberrations and sister chromatid exchange (SCE). Das and De (134) reported chromatid breaks as the main aberration in 100 patients with high blood Pb levels. Other chromosome abnormalities observed include chromosome breaks and dicentrics (109, 134). Older studies have reported no Pb-related increase in SCE frequency or have attributed an increase in that parameter to tobacco use in research subjects (135, 136). However, there are several recent studies (137–139) that associate Pb-exposure with an increase in SCE frequency.

Another marker of genotoxicity is micronucleation. Micronuclei are formed as a result of chromosome breaks (originated from unrepaired or incorrectly repaired DNA lesions) or mitotic spindle dysfunction. Their formation may be induced by oxidative stress or exposure to clastogens, including Pb (140–142). Balasubramanian et al. (143) reported an increase in MN frequency and DNA damage in workers exposed to Pb compared to the control group, which was related to years of exposure and accumulated genome damage.

Oxidative stress triggered by Pb can induce the formation of 8-hydroxy-2-deoxyguanosine (8-OHdG), which is a molecular marker for DNA oxidative damage. Its concentration in urine was reported to be significantly higher in workers exposed to Pb (144). Higher 8-OHdG levels were also reported in human lymphoblastoid TK6 cells exposed to Pb (145).

Another potential mechanism of Pb genotoxicity is the signalling pathway of the nuclear factor erythroid 2-related factor 2 (Nrf2). Nrf2 and NF- κ B are the two key transcriptional factors that interact to regulate cellular redox status in response to oxidative stress and inflammation, respectively. Pb-induced oxidative stress can disrupt this interaction impairs cell proliferation, cell cycle progression and, eventually, leads to cell death (146). Oxidative stress induced in bovine granulosa cells by Pb concentrations ranging from 1 to 10 $\mu\text{g}/\text{mL}$ downregulates both Nrf2 and NF- κ B and their downstream genes (147). Similar observations of oxidative stress, including downregulation of Nrf2, inflammation, and apoptosis were made in rat testis (148).

Mechanism of carcinogenicity

The IARC classifies Pb as a group 2A carcinogen (149). Pb-induced carcinogenicity is owed to increased oxidative stress, membrane alterations, impaired cell signalling, and impaired neurotransmission (150). It likely starts with ROS damaging the DNA, disrupting DNA repair and affecting genes that regulate the growth of tumour cells (151).

By inhibiting δ -aminolevulinic acid dehydratase, Pb favours the accumulation of ALA, which triggers ROS production, but also acts as a carcinogen (116). ALA-mediated oxidative DNA damage occurs through the production of 8-OHdG, 8-hydroxyguanine (8-oxo-7,8-dihydroguanine), and 8-oxo-7,8-dihydro-2-deoxyguanosine (8-oxodG) (116, 152). A number of studies has reported positive correlation between ALA levels and markers of oxidative stress and carcinogenesis (116, 137, 141, 153). Furthermore, hydroxyl radicals ($\text{HO}\cdot$) generated by ALA attack DNA strands and interact with its nucleobases to produce various oxidation products. All DNA nucleobases are susceptible to $\text{HO}\cdot$. The 8-oxodG lesion ($\text{HO}\cdot$ interaction with guanine) is the most abundant and is promutagenic (141). Unrepaired 8-oxodG can lead to genomic instability through transversions and the formation of double-strand breaks (116, 154). Furthermore, several studies (155–157) have revealed the epigenetic function of 8-oxodG, and its role in carcinogenesis through gene regulation.

CONCLUSION

This review sheds new light on the mechanisms of toxicity and genotoxicity of As and Pb. Both PTEs have been proven to affect various metabolic processes and impair the function of some organ systems, cause genetic damage, prevent DNA repair, and consequently promote carcinogenesis and tumour growth.

Both elements are still persistent in the environment, with millions of people at risk of exposure. In this sense, previously implemented strategies for preventing, monitoring, limiting and managing exposures to As, Pb, and other PTEs, heavy metals in particular, should be strictly followed. Engineering solutions can limit most occupational exposures, and it is essential to monitor

levels of heavy metals so that such solutions can be implemented. Good occupational hygiene is another effective method of limiting exposure.

Since both As and Pb are highly persistent in the environment, regardless of the fact that their primary sources have been removed, they still may contaminate water, soil, and food crops. To prevent and minimise secondary exposure, effective soil remediation and food monitoring are needed.

This review shows that the knowledge about both PTEs is still insufficient, and that it is necessary to regularly revise the existing concepts and accumulate data relevant for risk assessment. In this regard, it is recommended to focus on findings obtained using various sensitive genotoxicity tests and novel *-omics* approaches, which could help to better understand the process of carcinogenesis triggered by high levels of exposure to As and Pb.

Conflict of interests

None to declare.

Acknowledgements

Andrés Rodríguez Seijo would like to acknowledge the financial support of the Portuguese Foundation for Science and Technology (FCT) and the Interdisciplinary Centre of Marine and Environmental Research (CIIMAR) (grant references IDB/04423/2020, UIDP/04423/2020, LA/P/0101/2020, and CEECIND/03794/2017). He would also would like to thank the Spanish Ministry of Science, State Research Agency and the Universidade de Vigo for their financial support as part of the programme “Actuación financiada por IJC2020-044197-I/MCIN/AEI/10.13039/501100011033 y por la Unión Europea “NextGenerationEU”/PRTR”.

REFERENCES

1. Vithanage M, Kumarathilaka P, Oze C, Karunatilake S, Seneviratne M, Hseu ZY, Gunarathne V, Dassanayake M, Ok YS, Rinklebe J. Occurrence and cycling of trace elements in ultramafic soils and their impacts on human health: A critical review. *Environ Int* 2019;131:104974. doi: 10.1016/j.envint.2019.104974
2. Wu W, Qu S, Nel W, Ji J. The impact of natural weathering and mining on heavy metal accumulation in the karst areas of the Pearl River Basin, China. *Sci Total Environ* 2020;734:139480. doi: 10.1016/j.scitotenv.2020.139480
3. Hanfi MY, Mostafa MYA, Zhukovsky MV. Heavy metal contamination in urban surface sediments: sources, distribution, contamination control, and remediation. *Environ Monit Assess* 2019;192:32. doi: 10.1007/s10661-019-7947-5
4. Tchounwou PB, Yedjou CG, Patolla AK, Sutton DJ. Heavy metal toxicity and the environment. In: Luch A, editor. *Molecular, clinical and environmental toxicology*. Basel: Springer; 2012. p. 133–64.
5. Singh A, Chauhan S, Varjani S, Pandey A, Bhargava PC. Integrated approaches to mitigate threats from emerging potentially toxic elements: A way forward for sustainable environmental management. *Environ Res* 2022;209:112844. doi: 10.1016/j.envres.2022.112844
6. Jeong H, Ryu JS, Ra K. Characteristics of potentially toxic elements and multi-isotope signatures (Cu, Zn, Pb) in non-exhaust traffic emission sources. *Environ Pollut* 2022;292:118339. doi: 10.1016/j.envpol.2021.118339
7. Mohiuddin AK. Heavy metals: the notorious daredevils of daily personal care products. *Int J Pharm Pharm Res* 2019;2:8–18. doi: 10.21694/2642-2980.19008
8. WHO Regional Office for Europe & Joint WHO/Convention Task Force on the Health Aspects of Air Pollution. *Health Risks of Heavy Metals from Long-Range Transboundary Air Pollution*. Copenhagen: WHO Regional Office for Europe; 2007.
9. Fu X, Zhang H, Feng X, Tan Q, Ming L, Liu C, Zhang L. Domestic and transboundary sources of atmospheric particulate bound mercury in remote areas of China: evidence from mercury isotopes. *Environ Sci Technol* 2019;53:1947–57. doi: 10.1021/acs.est.8b06736
10. Natasha, Shahid M, Khalid S, Saleem M. Unrevealing arsenic and lead toxicity and antioxidant response in spinach: a human health perspective. *Environ Geochem Health* 2022;44:487–96. doi: 10.1007/s10653-021-00818-0
11. Alina M, Azrina A, Mohd Yunus A, Mohd Zakiuddin S, Mohd Izuan Effendi H, Muhammad Rizal R. Heavy metals (mercury, arsenic, cadmium, plumbum) in selected marine fish and shellfish along the Straits of Malacca. *Int Food Res J* 2012;19:135–40 [displayed 25 October 2022]. Available at [http://www.wifrij.upm.edu.my/19%20\(01\)%202011/\(18\)IFRJ-2010-235%20Alina.pdf](http://www.wifrij.upm.edu.my/19%20(01)%202011/(18)IFRJ-2010-235%20Alina.pdf)
12. Jaishankar M, Tseten T, Anbalagan N, Mathew BB, Beeregowda KN. Toxicity, mechanism and health effects of some heavy metals. *Interdiscip Toxicol* 2014;7:60–72. doi: 10.2478/intox-2014-0009
13. Engwa GA, Ferdinand PU, Nwalo FN, Unachukwu MN. Mechanism and health effects of heavy metal toxicity in humans. In: Karcioğlu O, Arslan B, editors. *Poisoning in the modern world - new tricks for an old dog?* London: IntechOpen; 2019. doi: 10.5772/intechopen.82511
14. Anyanwu BO, Ezeji for AN, Igweze ZN, Orisakwe OE. Heavy metal mixture exposure and effects in developing nations: an update. *Toxics* 2018;6(4):65. doi: 10.3390/toxics6040065
15. Leonard SS, Bower JJ, Shi X. Metal-induced toxicity, carcinogenesis, mechanisms and cellular responses. *Mol Cell Biochem* 2004;255:3–10. doi: 10.1023/b:mcbi.0000007255.72746.a6
16. Zhu Y, Costa M. Metals and molecular carcinogenesis. *Carcinogenesis* 2020;41:1161–72. doi: 10.1093/carcin/bgaa076
17. Fu Z, Xi S. The effects of heavy metals on human metabolism. *Toxicol Mech Methods* 2020;30:167–76. doi: 10.1080/15376516.2019.1701594
18. ARSDR Agency for Toxic Substances and Disease Registry. ATSDR's Substance Priority List, 2019 [displayed 08 September 2022]. Available at <https://www.atsdr.cdc.gov/spl/index.html>
19. Briffa J. Heavy Metals in Maltese Agricultural Soil. [Master thesis]. Malta: University of Malta; 2020.
20. Chung JY, Yu SD, Hong YS. Environmental source of arsenic exposure. *J Prev Med Public Health* 2014;47:253–7. doi: 10.3961/jpmph.14.036
21. Matta G, Gjiyli L. Mercury, lead and arsenic: impact on environment and human health. *J Chem Pharm Sci* 2016;9:718–25 [displayed 25 October 2022]. Available at [https://jchps.com/issues/Volume%209_Issue%202/jchps%209\(2\)%2010%20Gagan%20Matta.pdf](https://jchps.com/issues/Volume%209_Issue%202/jchps%209(2)%2010%20Gagan%20Matta.pdf)
22. Kuivenhoven M, Mason K. *Arsenic Toxicity*. [Updated 2022 Jun 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;

- 2022 Jan [displayed 27 October 2022]. Available at <https://www.ncbi.nlm.nih.gov/books/NBK541125/>
23. Chávez-Capilla T. The need to unravel arsenolipid transformations in humans. *DNA Cell Biol* 2022;41:64–70. doi: 10.1089/dna.2021.0476
 24. Sanyal T, Bhattacharjee P, Paul S, Bhattacharjee P. Recent advances in arsenic research: significance of differential susceptibility and sustainable strategies for mitigation. *Front Public Health* 2020;8:464. doi: 10.3389/fpubh.2020.00464
 25. Pakulska D, Czerczak S. Hazardous effects of arsine: a short review. *Int J Occup Med Environ Health* 2006;19:36–44. doi: 10.2478/v10001-006-0003-z
 26. Nieuwenhuijsen MJ, Toledano MB, Eaton NE, Fawell J, Elliott P. Chlorination disinfection byproducts in water and their association with adverse reproductive outcomes: a review. *Occup Environ Med* 2000;57:73–85. doi: 10.1136/oem.57.2.73
 27. Zuzolo D, Cicchella D, Demetriades A, Birke M, Albanese S, Dinelli E, Lima A, Valera P, De Vivo B. Arsenic: Geochemical distribution and age-related health risk in Italy. *Environ Res* 2020;182:109076. doi: 10.1016/j.envres.2019.109076
 28. Briffa J, Sinagra E, Blundell R. Heavy metal pollution in the environment and their toxicological effects on humans. *Heliyon* 2020;6(9):e04691. doi: 10.1016/j.heliyon.2020.e04691
 29. Blessing Ebele O. Mechanisms of arsenic toxicity and carcinogenesis. *Afr J Biochem Res* 2009;3(5):232–7.
 30. Twaddle NC, Vanlandingham M, Beland FA, Doerge DR. Metabolism and disposition of arsenic species from controlled dosing with dimethylarsinic acid (DMA^V) in adult female CD-1 mice. V. Toxicokinetic studies following oral and intravenous administration. *Food Chem Toxicol* 2019;130:22–31. doi: 10.1016/j.fct.2019.04.045
 31. Yu H, Liu S, Li M, Wu B. Influence of diet, vitamin, tea, trace elements and exogenous antioxidants on arsenic metabolism and toxicity. *Environ Geochem Health* 2016;38:339–51. doi: 10.1007/s10653-015-9742-8
 32. Hu Y, Li J, Lou B, Wu R, Wang G, Lu C, Wang H, Pi J, Xu Y. The role of reactive oxygen species in arsenic toxicity. *Biomolecules* 2020;10(2):240. doi: 10.3390/biom10020240
 33. Kligerman A, Tennant A. Insights into the carcinogenic mode of action of arsenic. *Toxicol Appl Pharmacol* 2007;222:281–8. doi: 10.1016/j.taap.2006.10.006
 34. Ng JC. Environmental contamination of arsenic and its toxicological impact on humans. *Environ Chem* 2005;2:146–60. doi: 10.1071/EN05062
 35. Kitchin KT, Conolly R. Arsenic-induced carcinogenesis - oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment. *Chem Res Toxicol* 2010;23:327–35. doi: 10.1021/tx900343d
 36. Palma-Lara I, Martínez-Castillo M, Quintana-Pérez JC, Arellano-Mendoza MG, Tamay-Cach F, Valenzuela-Limón OL, García-Montalvo EA, Hernández-Zavala A. Arsenic exposure: a public health problem leading to several cancers. *Regul Toxicol Pharmacol* 2020;110:104539. doi: 10.1016/j.yrtph.2019.104539
 37. Zhou Q, Xi S. A review on arsenic carcinogenesis: epidemiology, metabolism, genotoxicity and epigenetic changes. *Regul Toxicol Pharmacol* 2018;99:78–88. doi: 10.1016/j.yrtph.2018.09.010
 38. Rhodes CE, Denault D, Varacallo M. Physiology, Oxygen Transport. [Updated 2021 Nov 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan [displayed 27 October 2022]. Available at <https://www.ncbi.nlm.nih.gov/books/NBK538336/>
 39. Hughes MF. Arsenic toxicity and potential mechanisms of action. *Toxicol Lett* 2002;133:1–16. doi: 10.1016/s0378-4274(02)00084-x
 40. Kulshrestha A, Jarouliya U, Prasad G, Flora S, Bisen PS. Arsenic-induced abnormalities in glucose metabolism: biochemical basis and potential therapeutic and nutritional interventions. *World J Transl Med* 2014;3:96–111. doi: 10.5528/wjtm.v3.i2.96
 41. Fan C, Liu G, Long Y, Rosen B, Cai Y. Thiolation in arsenic metabolism: a chemical perspective. *Metallomics* 2018;10:1368–82. doi: 10.1039/c8mt00231b
 42. Walton FS, Harmon AW, Paul DS, Drobná Z, Patel YM, Styblo M. Inhibition of insulin-dependent glucose uptake by trivalent arsenicals: possible mechanism of arsenic-induced diabetes. *Toxicol Appl Pharmacol* 2004;198:424–33. doi: 10.1016/j.taap.2003.10.026
 43. Styblo M, Venkatratnam A, Fry RC, Thomas DJ. Origins, fate, and actions of methylated trivalent metabolites of inorganic arsenic: progress and prospects. *Arch Toxicol* 2021;95:1547–72. doi: 10.1007/s00204-021-03028-w
 44. Srivastava S, Flora SJ. Arsenicals: toxicity, their use as chemical warfare agents, and possible remedial measures. In: Gupta RC, editor. *Handbook of toxicology of chemical warfare agents*. Cambridge: Academic Press; 2020. p. 303–19.
 45. Liu Y, Zhao H, Wang Y, Guo M, Mu M, Xing M. Arsenic (III) and/or copper (II) induces oxidative stress in chicken brain and subsequent effects on mitochondrial homeostasis and autophagy. *J Inorg Biochem* 2020;211:111201. doi: 10.1016/j.jinorgbio.2020.111201
 46. Li JX, Shen YQ, Cai BZ, Zhao J, Bai X, Lu YJ, Li XQ. Arsenic trioxide induces the apoptosis in vascular smooth muscle cells via increasing intracellular calcium and ROS formation. *Mol Biol Rep* 2010;37:1569–76. doi: 10.1007/s11033-009-9561-z
 47. Lynn S, Gurr JR, Lai HT, Jan KY. NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. *Circ Res* 2000;86:514–9. doi: 10.1161/01.res.86.5.514
 48. Liu SX, Athar M, Lippai I, Waldren C, Hei TK. Induction of oxyradicals by arsenic: implication for mechanism of genotoxicity. *Proc Natl Acad Sci USA* 2001;98:1643–8. doi: 10.1073/pnas.98.4.1643
 49. Tam LM, Wang Y. Arsenic exposure and compromised protein quality control. *Chem Res Toxicol* 2020;33:1594–604. doi: 10.1021/acs.chemrestox.0c00107
 50. Valko M, Jomova K, Rhodes CJ, Kuča K, Musilek K. Redox- and non-redox-metal-induced formation of free radicals and their role in human disease. *Arch Toxicol* 2016;90:1–37. doi: 10.1007/s00204-015-1579-5
 51. Ran S, Liu J, Li S. A Systematic review of the various effect of arsenic on glutathione synthesis *in vitro* and *in vivo*. *Biomed Res Int* 2020;2020:9414196. doi: 10.1155/2020/9414196
 52. Singh R, Misra AN, Sharma P. Effect of arsenate toxicity on antioxidant enzymes and expression of nicotianamine synthase in contrasting genotypes of bioenergy crop *Ricinus communis*. *Environ Sci Pollut Res Int* 2021;28:31421–30. doi: 10.1007/s11356-021-12701-7
 53. Askevold JE. Arsenic and ADHD-Perinatal exposure to Arsenic species in breastmilk and ADHD in adolescents [Project thesis]. Oslo: Faculty of Medicine, University of Oslo; 2022 [displayed 27 October 2022]. Available at <https://www.duo.uio.no/bitstream/handle/10852/94054/1/Kappe-Arsenic-og-ADHD.pdf>
 54. Meyer S, Schulz J, Jeibmann A, Taleshi MS, Ebert F, Francesconi KA, Schwerdtle T. Arsenic-containing hydrocarbons are toxic in the *in vivo*

- model *Drosophila melanogaster*. *Metallomics* 2014;6:2010–4. doi: 10.1039/c4mt00249k
55. Niehoff AC, Schulz J, Soltwisch J, Meyer S, Kettling H, Sperling M, Jeibmann A, Dreisewerd K, Francesconi KA, Schwerdtle T, Karst U. Imaging by elemental and molecular mass spectrometry reveals the uptake of an arsenolipid in the brain of *Drosophila melanogaster*. *Anal Chem* 2016;88:5258–63. doi: 10.1021/acs.analchem.6b00333
56. Xue XM, Xiong C, Yoshinaga M, Rosen B, Zhu YG. The enigma of environmental organoarsenicals: insights and implications. *Crit Rev Environ Sci Technol* 2022;52:3835–62. doi: 10.1080/10643389.2021.1947678
57. Mac Monagail M, Morrison L. Arsenic speciation in a variety of seaweeds and associated food products. *Compr Anal Chem* 2019;85:267–310. doi: 10.1016/bs.coac.2019.03.005
58. Flora SJ. Arsenic-induced oxidative stress and its reversibility. *Free Radic Biol Med* 2011;51:257–81. doi: 10.1016/j.freeradbiomed.2011.04.008
59. Liu G, Song Y, Li C, Liu R, Chen Y, Yu L, Huang Q, Zhu D, Lu C, Yu X, Xiao C, Liu Y. Arsenic compounds: the wide application and mechanisms applied in acute promyelocytic leukemia and carcinogenic toxicology. *Eur J Med Chem* 2021;221:113519. doi: 10.1016/j.ejmech.2021.113519
60. Martin EM, Fry RC. Environmental influences on the epigenome: exposure-associated DNA methylation in human populations. *Annu Rev Public Health* 2018;39:309–33. doi: 10.1146/annurev-publhealth-040617-014629
61. Nuta O, Bouffler S, Lloyd D, Ainsbury E, Sepai O, Rothkamm K. Investigating the impact of long term exposure to chemical agents on the chromosomal radiosensitivity using human lymphoblastoid GM1899A cells. *Sci Rep* 2021;11:12616. doi: 10.1038/s41598-021-91957-y
62. Patlolla AK, Todorov TI, Tchounwou PB, van der Voet G, Centeno JA. Arsenic-induced biochemical and genotoxic effects and distribution in tissues of Sprague-Dawley rats. *Microchem J* 2012;105:101–7. doi: 10.1016/j.microc.2012.08.013
63. Demanelis K, Argos M, Tong L, Shinkle J, Sabarinathan M, Rakibuz-Zaman M, Sarwar G, Shahriar H, Islam T, Rahman M, Yunus M, Graziano JH, Broberg K, Engström K, Jasmine F, Ahsan H, Pierce BL. Association of arsenic exposure with whole blood DNA methylation: an epigenome-wide study of Bangladeshi adults. *Environ Health Perspect* 2019;127(5):057011. doi: 10.1289/EHP3849
64. Tam LM, Price NE, Wang Y. Molecular mechanisms of arsenic-induced disruption of DNA repair. *Chem Res Toxicol* 2020;33:709–26. doi: 10.1021/acs.chemrestox.9b00464
65. Moura DJ, Péres VF, Jacques RA, Saffi J. Heavy metal toxicity: oxidative stress parameters and DNA repair. In: Gupta D, Sandalio L, editors. *Metal toxicity in plants: perception, signaling and remediation*. Berlin, Heidelberg: Springer; 2012. p. 187–205. doi: 10.1007/978-3-642-22081-4_9
66. Kligerman AD, Doerr CL, Tennant AH, Harrington-Brock K, Allen JW, Winkfield E, Poorman-Allen P, Kundu B, Funasaka K, Roop BC, Mass MJ, DeMarini DM. Methylated trivalent arsenicals as candidate ultimate genotoxic forms of arsenic: induction of chromosomal mutations but not gene mutations. *Environ Mol Mutagen* 2003;42:192–205. doi: 10.1002/em.10192
67. Renu K, Saravanan A, Elangovan A, Ramesh S, Annamalai S, Namachivayam A, Abel P, Madhyastha H, Madhyastha R, Maruyama M, Balachandar V, Valsala Gopalakrishnan A. An appraisal on molecular and biochemical signalling cascades during arsenic-induced hepatotoxicity. *Life Sci* 2020;260:118438. doi: 10.1016/j.lfs.2020.118438
68. Tchounwou PB, Centeno JA, Patlolla AK. Arsenic toxicity, mutagenesis, and carcinogenesis - a health risk assessment and management approach. *Mol Cell Biochem* 2004;255:47–55. doi: 10.1023/b:mcbi.0000007260.32981.b9
69. Nasrollahzadeh A, Bashash D, Kabuli M, Zandi Z, Kashani B, Zaghali A, Mousavi SA, Ghaffari SH. Arsenic trioxide and BIBR1532 synergistically inhibit breast cancer cell proliferation through attenuation of NF- κ B signaling pathway. *Life Sci* 2020;257:118060. doi: 10.1016/j.lfs.2020.118060
70. Wei M, Liu J, Xu M, Rui D, Xu S, Feng G, Ding Y, Li S, Guo S. Divergent effects of arsenic on NF- κ B signaling in different cells or tissues: a systematic review and meta-analysis. *Int J Environ Res Public Health* 2016;13(2):163. doi: 10.3390/ijerph13020163
71. Oeckinghaus A, Ghosh S. The NF- κ B family of transcription factors and its regulation. *Cold Spring Harb Perspect Biol* 2009;1(4):a000034. doi: 10.1101/cshperspect.a000034
72. Jin W, Xue Y, Xue Y, Han X, Song Q, Zhang J, Li Z, Cheng J, Guan S, Sun S, Chu L. Tannic acid ameliorates arsenic trioxide-induced nephrotoxicity, contribution of NF- κ B and Nrf2 pathways. *Biomed Pharmacother* 2020;126:110047. doi: 10.1016/j.biopha.2020.110047
73. Karin M, Delhase M. The I κ B kinase (IKK) and NF- κ B: key elements of proinflammatory signalling. *Semin Immunol* 2000;12:85–98. doi: 10.1006/smim.2000.0210
74. Chen F, Shi X. Signaling from toxic metals to NF- κ B and beyond: not just a matter of reactive oxygen species. *Environ Health Perspect* 2002;110(Suppl 5):807–11. doi: 10.1289/ehp.02110s5807
75. Medda N, De SK, Maiti S. Different mechanisms of arsenic related signaling in cellular proliferation, apoptosis and neo-plastic transformation. *Ecotoxicol Environ Saf* 2021;208:111752. doi: 10.1016/j.ecoenv.2020.111752
76. He X, Ma Q. NRF2 cysteine residues are critical for oxidant/electrophile-sensing, Kelch-like ECH-associated protein-1-dependent ubiquitination-proteasomal degradation, and transcription activation. *Mol Pharmacol* 2009;76:1265–78. doi: 10.1124/mol.109.058453
77. He X, Wang L, Szklarz G, Bi Y, Ma Q. Resveratrol inhibits paraquat-induced oxidative stress and fibrogenic response by activating the nuclear factor erythroid 2-related factor 2 pathway. *J Pharmacol Exp Ther* 2012;342:81–90. doi: 10.1124/jpet.112.194142
78. Zhong L, Hao H, Chen D, Hou Q, Zhu Z, He W, Sun S, Sun M, Li M, Fu X. Arsenic trioxide inhibits the differentiation of fibroblasts to myofibroblasts through nuclear factor erythroid 2-like 2 (NFE2L2) protein and the Smad2/3 pathway. *J Cell Physiol* 2019;234:2606–17. doi: 10.1002/jcp.27073
79. Massrich W, Derjuga A, Blank V. Induction of endogenous Nrf2/small maf heterodimers by arsenic-mediated stress in placental choriocarcinoma cells. *Antioxid Redox Signal* 2006;8:53–9. doi: 10.1089/ars.2006.8.53
80. Wang L, Kou MC, Weng CY, Hu LW, Wang YJ, Wu MJ. Arsenic modulates heme oxygenase-1, interleukin-6, and vascular endothelial growth factor expression in endothelial cells: roles of ROS, NF- κ B, and MAPK pathways. *Arch Toxicol* 2012;86:879–96. doi: 10.1007/s00204-012-0845-z
81. Eckstein M, Eleazer R, Rea M, Fondufe-Mittendorf Y. Epigenomic reprogramming in inorganic arsenic-mediated gene expression patterns during carcinogenesis. *Rev Environ Health* 2017;32:93–103. doi: 10.1515/revh-2016-0025

82. Thomas DJ. Arsenic methylation - Lessons from three decades of research. *Toxicology* 2021;457:152800. doi: 10.1016/j.tox.2021.152800
83. Cheng TF, Choudhuri S, Muldoon-Jacobs K. Epigenetic targets of some toxicologically relevant metals: a review of the literature. *J Appl Toxicol* 2012;32:643–53. doi: 10.1002/jat.2717
84. Mukhopadhyay P, Greene RM, Pisano MM. Cigarette smoke induces proteasomal-mediated degradation of DNA methyltransferases and methyl CpG-/CpG domain-binding proteins in embryonic orofacial cells. *Reprod Toxicol* 2015;58:140–8. doi: 10.1016/j.reprotox.2015.10.009
85. Pogribna M, Hammons G. Epigenetic effects of nanomaterials and nanoparticles. *J Nanobiotechnology* 2021;19:2. doi: 10.1186/s12951-020-00740-0
86. Li H, He J, Ju P, Zhong X, Liu J. Studies on the mechanism of arsenic trioxide-induced apoptosis in HepG₂ human hepatocellular carcinoma cells. *Chin J Clin Oncol* 2008;5:22–5. doi: 10.1007/s11805-008-0022-6
87. Cai X, Yu L, Chen Z, Ye F, Ren Z, Jin P. Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1. *Cancer Biomark* 2020;28:221–30. doi: 10.3233/cbm-190490
88. Jing-Jing Z, Xiao-Jie C, Wen-Dong Y, Ying-Hui W, Hang-Sheng Z, Hong-Yue Z, Zhi-Hong Z, Bin-Hui W, Fan-Zhu. Fabrication of a folic acid-modified arsenic trioxide prodrug liposome and assessment of its anti-hepatocellular carcinoma activity. *Dig Chin Med* 2020;3:260–74. doi: 10.1016/j.demed.2020.12.005
89. Zhang F, Duan J, Song H, Yang L, Zhou M, Wang X. Combination of canstatin and arsenic trioxide suppresses the development of hepatocellular carcinoma. *Drug Dev Res* 2021;82:430–9. doi: 10.1002/ddr.21766
90. Chen Y, Li H, Chen D, Jiang X, Wang W, Li D, Shan H. Hypoxic hepatocellular carcinoma cells acquire arsenic trioxide resistance by upregulating HIF-1 α expression. *Dig Dis Sci* 2022;67:3806–16. doi: 10.1007/s10620-021-07202-z
91. Fang Y, Zhang Z. Arsenic trioxide as a novel anti-glioma drug: a review. *Cell Mol Biol Lett* 2020;25:44. doi: 10.1186/s11658-020-00236-7
92. Siddique R, Khan S, Bai Q, Li H, Ullah MW, Xue M. Arsenic Trioxide-based nanomedicines as a therapeutic combination approach for treating gliomas: a review. *Curr Nanosci* 2021;17:406–17. doi: 10.2174/1573413716999201207142810
93. Sönksen M, Kerl K, Bunzen H. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors. *Med Res Rev* 2021;42:374–98. doi: 10.1002/med.21844
94. Genchi G, Lauria G, Catalano A, Carocci A, Sinicropi MS. Arsenic: a review on a great health issue worldwide. *Appl Sci* 2022;12(12):6184. doi: 10.3390/app12126184
95. Gamboa-Loira B, Cebrían ME, Franco-Marina F, López-Carrillo L. Arsenic metabolism and cancer risk: a meta-analysis. *Environ Res* 2017;156:551–8. doi: 10.1016/j.envres.2017.04.016
96. Nurchi VM, Djordjevic AB, Crisponi G, Alexander J, Bjørklund G, Aaseth J. Arsenic toxicity: molecular targets and therapeutic agents. *Biomolecules* 2020;10(2):235. doi: 10.3390/biom10020235
97. Wani A, Ara A, Usmani JA. Lead toxicity: a review. *Interdiscip Toxicol* 2015;8:55–64. doi: 10.1515/intox-2015-0009
98. Çelebi H, Gök G, Gök O. Adsorption capability of brewed tea waste in waters containing toxic lead(II), cadmium(II), nickel(II), and zinc(II) heavy metal ions. *Sci Rep* 2020;10(1):17570. doi: 10.1038/s41598-020-74553-4
99. World Health Organization. Lead poisoning [displayed 5 September 2022]. Available at <https://www.who.int/news-room/fact-sheets/detail/lead-poisoning-and-health>
100. Charkiewicz AE, Backstrand JR. Lead toxicity and pollution in Poland. *Int J Environ Res Public Health* 2020;17(12):4385. doi: 10.3390/ijerph17124385
101. Rehman K, Fatima F, Waheed I, Akash MSH. Prevalence of exposure of heavy metals and their impact on health consequences. *J Cell Biochem* 2018;119:157–84. doi: 10.1002/jcb.26234
102. Samarghandian S, Shirazi FM, Saeedi F, Roshanravan B, Pourbagher-Shahri AM, Khorasani EY, Farkhondeh T, Aaseth JO, Abdollahi M, Mehrpour O. A systematic review of clinical and laboratory findings of lead poisoning: lessons from case reports. *Toxicol Appl Pharmacol* 2021;429:115681. doi: 10.1016/j.taap.2021.115681
103. Papanikolaou NC, Hatzidaki EG, Belivanis S, Tzanakakis GN, Tsatsakis AM. Lead toxicity update. A brief review. *Med Sci Monit* 2005;11(10):RA329–36. PMID: 16192916
104. Centers for Disease Control and Prevention. Low Level Lead Exposure Harms Children: A Renewed Call for Primary Prevention - Report of the Advisory Committee on Childhood Lead Poisoning Prevention of the Centers for Disease Control and Prevention, 2012 [displayed 28 October 2022]. Available at http://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf
105. Raymond J, Brown MJ. Childhood blood lead levels in children aged <5 years - United States, 2009–2014. *MMWR Surveill Summ* 2017;66:1–10. doi: 10.15585/mmwr.ss6603a1
106. Dignam T, Kaufmann RB, LeSturgeon L, Brown MJ. Control of lead sources in the United States, 1970–2017: Public health progress and current challenges to eliminating lead exposure. *J Public Health Manag Pract* 2019;25(Suppl 1):S13–22. doi: 10.1097/phh.0000000000000889
107. Flannery BM, Middleton KB. Updated interim reference levels for dietary lead to support FDA's Closer to Zero action plan. *Regul Toxicol Pharmacol* 2022;133:105202. doi: 10.1016/j.yrtph.2022.105202
108. Lubos E, Loscalzo J, Handy DE. Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. *Antioxid Redox Signal* 2011;15(7):1957–97. doi: 10.1089/ars.2010.3586
109. Mitra P, Sharma S, Purohit P, Sharma P. Clinical and molecular aspects of lead toxicity: An update. *Crit Rev Clin Lab Sci* 2017;54:506–28. doi: 10.1080/10408363.2017.1408562
110. Flora G, Gupta D, Tiwari A. Toxicity of lead: A review with recent updates. *Interdiscip Toxicol* 2012;5(2):47–58. doi: 10.2478/v10102-012-0009-2
111. Obeng-Gyasi E. Lead exposure and oxidative stress - A life course approach in US adults. *Toxics* 2018;6(3):42. doi: 10.3390/toxics6030042
112. Jiang X, Xing X, Zhang Y, Zhang C, Wu Y, Chen Y, Meng R, Jia H, Cheng Y, Zhang Y, Su J. Lead exposure activates the Nrf2/Keap1 pathway, aggravates oxidative stress, and induces reproductive damage in female mice. *Ecotoxicol Environ Saf* 2021;207:111231. doi: 10.1016/j.ecoenv.2020.111231
113. Gurer-Orhan H, Sabir HU, Özgünes H. Correlation between clinical indicators of lead poisoning and oxidative stress parameters in controls and lead-exposed workers. *Toxicology* 2004;195:147–54. doi: 10.1016/j.tox.2003.09.009
114. La-Llave-León O, Méndez-Hernández EM, Castellanos-Juárez FX, Esquivel-Rodríguez E, Vázquez-Alaniz F, Sandoval-Carrillo A, García-Vargas G, Duarte-Sustaita J, Candelas-Rangel JL, Salas-Pacheco JM. Association between blood lead levels and delta-aminolevulinic acid

- dehydratase in pregnant women. *Int J Environ Res Public Health* 2017;14(4):432. doi: 10.3390/ijerph14040432
115. Andrade V, Mateus ML, Batoréu, MC, Aschner M, Dos Santos AM. Urinary delta-ALA: a potential biomarker of exposure and neurotoxic effect in rats co-treated with a mixture of lead, arsenic and manganese. *Neurotoxicology* 2013;38:33–41. doi: 10.1016/j.neuro.2013.06.003
116. Ibrahim S, Hassan M, Ibraheem Q, Arif K. Genotoxic effect of lead and cadmium on workers at wastewater plant in Iraq. *J Environ Public Health* 2020;2020:9171027. doi: 10.1155/2020/9171027
117. Sridevi SK, Umamaheswari S. Human exposure to lead, mechanism of toxicity and treatment strategy - a review. *J Clin Diagnostic Res* 2020;14(12):LE01–5. doi: 10.7860/JCDR/2020/45615.14345
118. Patra R, Rautray AK, Swarup D. Oxidative stress in lead and cadmium toxicity and its amelioration. *Vet Med Int* 2011;2011:457327. doi: 10.4061/2011/457327
119. Wyparło-Wszelaki M, Wąsik M, Machoń-Grecka A, Kasperczyk A, Bellanti F, Kasperczyk S, Dobrakowski M. Blood magnesium level and selected oxidative stress indices in lead-exposed workers. *Biol Trace Elem Res* 2021;199:465–72. doi: 10.1007/s12011-020-02168-x
120. Adeyemi WJ, Abdussalam TA, Abdulrahim A, Olayaki LA. Elevated, sustained, and yet reversible biotoxicity effects of lead on cessation of exposure: Melatonin is a potent therapeutic option. *Toxicol Ind Health* 2020;36:477–86. doi: 10.1177/0748233720937199
121. Virgolini MB, Aschner M. Molecular mechanisms of lead neurotoxicity. *Adv Neurotoxicol* 2021;5:159–213. doi: 10.1016/bs.ant.2020.11.002
122. Jangid AP, Shekhawat V, Pareek H, Yadav D, Sharma P, John P. Effect of lead on human blood antioxidant enzymes and glutathione. *Int J Biochem Res Rev* 2016;13(1):1–9.
123. Kshirsagar MS, Patil JA, Patil A. Increased blood lead level induces oxidative stress and alters the antioxidant status of spray painters. *J Basic Clin Physiol Pharmacol* 2020;31(2):20180229. doi: 10.1515/jbcp-2018-0229
124. Sadhu HG, Amin BK, Parikh DJ, Sathawara NG, Mishra U, Virani BK, Lakkad BC, Shivgotra VK, Patel S. Poisoning of workers working in small lead-based units. *Indian J Occup Environ Med* 2008;12:139–41. doi: 10.4103/0019-5278.44697
125. Sirati-Sabet M, Asadikaram G, Ilghari D, Gheibi N, Torkman F, Abdolvahabi Z, Khabbaz F. The effect of lead on erythrocyte glucose-6-phosphate dehydrogenase activity in rats. *Biotech Health Sci* 2014;1(1):e19192. doi: 10.17795/bhs-19192
126. Flora S, Mittal M, Mehta A. Heavy metal induced oxidative stress and its possible reversal by chelation therapy. *Indian J Med Res* 2008;128:501–23. PMID: 19106443
127. Lachant NA, Tomoda A, Tanaka KR. Inhibition of the pentose phosphate shunt by lead: a potential mechanism for hemolysis in lead poisoning. *Blood* 1984;63:518–24. doi: 10.1182/blood.V63.3.518.518
128. Moniuszko-Jakoniuk J, Jurczuk M, Brzóska MM. Evaluation of glutathione-related enzyme activities in the liver and kidney of rats exposed to lead and ethanol. *Pharmacol Rep* 2007;59(Suppl 1):217–25.
129. Dobrakowski M, Pawlas N, Kasperczyk A, Kozłowska A, Olewińska E, Machoń-Grecka A, Kasperczyk S. Oxidative DNA damage and oxidative stress in lead-exposed workers. *Hum Exp Toxicol* 2017;36:744–54. doi: 10.1177/0960327116665674
130. Simons T. Lead-calcium interactions and lead toxicity. In: Baker PF, editor. *Calcium in drug actions. Handbook of experimental pharmacology*. Vol 83. Berlin, Heidelberg: Springer; 1988. p. 509–25. doi: 10.1007/978-3-642-71806-9_24
131. Rădulescu A, Lundgren S. A pharmacokinetic model of lead absorption and calcium competitive dynamics. *Sci Rep* 2019;9:14225. doi: 10.1038/s41598-019-50654-7
132. García-Lestón J, Méndez J, Pásaro E, Laffon B. Genotoxic effects of lead: an updated review. *Environ Int* 2010;36:623–36. doi: 10.1016/j.envint.2010.04.011
133. Sachdeva C, Thakur K, Sharma A, Sharma KK. Lead: tiny but mighty poison. *Indian J Clin Biochem* 2018;33:132–46. doi: 10.1007/s12291-017-0680-3
134. Das U, De M. Chromosomal study on lead exposed population. *Int J Hum Genet* 2013;13:53–8. doi: 10.1080/09723757.2013.11886197
135. Pinto D, Ceballos JM, García G, Guzmán P, Del Razo LM, Vera E, Gómez H, García A, Gosebatt ME. Increased cytogenetic damage in outdoor painters. *Mutat Res* 2000;467:105–11. doi: 10.1016/s1383-5718(00)00024-3
136. Rajah T, Ahuja Y. *In vivo* genotoxic effects of smoking and occupational lead exposure in printing press workers. *Toxicol Lett* 1995;76:71–5. doi: 10.1016/0378-4274(94)03200-9
137. Duydu Y, Süzen HS. Influence of δ -aminolevulinic acid dehydratase (ALAD) polymorphism on the frequency of sister chromatid exchange (SCE) and the number of high-frequency cells (HFCs) in lymphocytes from lead-exposed workers. *Mutat Res* 2003;540:79–88. doi: 10.1016/s1383-5718(03)00172-4
138. Palus J, Ryzdyski K, Dziubaltowska E, Wyszynska K, Natarajan AT, Nilsson R. Genotoxic effects of occupational exposure to lead and cadmium. *Mutat Res* 2003;540:19–28. doi: 10.1016/S1383-5718(03)00167-0
139. Wiwanitkit V, Suwansaksri J, Soogarun S. White blood cell sister chromatid exchange among a sample of Thai subjects exposed to lead: lead-induced genotoxicity. *Toxicol Environ Chem* 2008;90:765–8. doi: 10.1080/02772240701712758
140. Bonassi S, Znaor A, Ceppi M, Lando C, Chang WP, Holland N, Kirsch-Volders M, Zeiger E, Ban S, Barale R, Bigatti MP, Bolognesi C, Cebulka-Wasilewska A, Fabianova E, Fucic A, Hagmar L, Joksic G, Martelli A, Migliore L, Mirkova E, Scarfi MR, Zijno A, Norppa H, Fenech M. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. *Carcinogenesis* 2007;28:625–31. doi: 10.1093/carcin/bgl177
141. Celik A, Ögöner O, Çömelekoğlu Ü. The evaluation of micronucleus frequency by acridine orange fluorescent staining in peripheral blood of rats treated with lead acetate. *Mutagenesis* 2005;20:411–5. doi: 10.1093/mutage/gei055
142. Nersesyan A, Kundi M, Waldherr M, Setayesh T, Mišik M, Wultsch G, Filipic M, Mazzaron Barcelos GR, Knasmueller S. Results of micronucleus assays with individuals who are occupationally and environmentally exposed to mercury, lead and cadmium. *Mutat Res Rev Mutat Res* 2016;770:119–39. doi: 10.1016/j.mrrev.2016.04.002
143. Balasubramanian B, Meyyazhagan A, Chinnappan AJ, Alagamuthu KK, Shanmugam S, Al-Dhabi NA, Mohammed Ghilan AK, Duraipandian V, Valan Arasu M. Occupational health hazards on workers exposure to lead (Pb): A genotoxicity analysis. *J Infect Public Health* 2020;13:527–31. doi: 10.1016/j.jiph.2019.10.005
144. Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2'-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev* 2009;27:120–39. doi: 10.1080/10590500902885684
145. Liu X, Wu J, Shi W, Shi W, Liu H, Wu X. Lead induces genotoxicity via oxidative stress and promoter methylation of DNA repair genes

- in human lymphoblastoid TK6 cells. *Med Sci Monit* 2018;24:4295–304. doi: 10.12659/msm.908425
146. Buha A, Baralić K, Djukic-Cosic D, Bulat Z, Tinkov A, Panieri E, Saso L. The role of toxic metals and metalloids in Nrf2 signaling. *Antioxidants* 2021;10(5):630. doi: 10.3390/antiox10050630
 147. Aglan HS, Gebremedhn S, Salilew-Wondim D, Neuhof C, Tholen E, Holker M, Schellander K, Tesfaye D. Regulation of Nrf2 and NF- κ B during lead toxicity in bovine granulosa cells. *Cell Tissue Res* 2020;380:643–55. doi: 10.1007/s00441-020-03177-x
 148. Alotaibi MF, Al-Joufi F, Abou Seif HS, Alzoghbi MA, Djouhri L, Ahmeda AF, Mahmoud AM. Umbelliferone inhibits spermatogenic defects and testicular injury in lead-intoxicated rats by suppressing oxidative stress and inflammation, and improving Nrf2/HO-1 signaling. *Drug Des Devel Ther* 2020;14:4003–19. doi: 10.2147/dddt.s265636
 149. World Health Organization, International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Inorganic and Organic Lead Compounds. Vol. 87. Inorganic and Organic Lead, 2006 [displayed 28 October 2022]. Available at <https://monographs.iarc.who.int/wp-content/uploads/2018/06/mono87.pdf>
 150. Wallace DR, Djordjevic AB. Heavy metal and pesticide exposure: A mixture of potential toxicity and carcinogenicity. *Curr Opin Toxicol* 2020;19:72–9. doi: 10.1016/j.cotox.2020.01.001
 151. Chen QY, DesMarais T, Costa M. Metals and mechanisms of carcinogenesis. *Annu Rev Pharmacol Toxicol* 2019;59:537–54. doi: 10.1146/annurev-pharmtox-010818-021031
 152. Fraga CG, Onuki J, Lucesoli F, Bechara EJ, Di Mascio P. 5-Aminolevulinic acid mediates the *in vivo* and *in vitro* formation of 8-hydroxy-2'-deoxyguanosine in DNA. *Carcinogenesis* 1994;15:2241–4. doi: 10.1093/carcin/15.10.2241
 153. Xu X, Liao W, Lin Y, Dai Y, Shi Z, Huo X. Blood concentrations of lead, cadmium, mercury and their association with biomarkers of DNA oxidative damage in preschool children living in an e-waste recycling area. *Environ Geochem Health* 2018;40:1481–94. doi: 10.1007/s10653-017-9997-3
 154. Gorini F, Scala G, Cooke MS, Majello B, Amente S. Towards a comprehensive view of 8-oxo-7,8-dihydro-2'-deoxyguanosine: highlighting the intertwined roles of DNA damage and epigenetics in genomic instability. *DNA Repair* 2021;97:103027. doi: 10.1016/j.dnarep.2020.103027
 155. Cogo S, Ferino A, Miglietta G, Pedersen EB, Xodo LE. The regulatory G4 motif of the Kirsten ras (KRAS) gene is sensitive to guanine oxidation: implications on transcription. *Nucleic Acids Res* 2018;46:661–76. doi: 10.1093/nar/gkx1142
 156. Fleming AM, Ding Y, Burrows CJ. Oxidative DNA damage is epigenetic by regulating gene transcription via base excision repair. *Proc Natl Acad Sci USA* 2017;114:2604–9. doi: 10.1073/pnas.1619809114
 157. Giorgio M, Dellino GI, Gambino V, Roda N, Pelicci PG. On the epigenetic role of guanosine oxidation. *Redox Biol* 2020;29:101398. doi: 10.1016/j.redox.2019.101398

Metabolički i genski poremećaji – pregled mehanizama toksičnosti i genotoksičnosti arsena i olova

Urbanizacija i industrijalizacija su u porastu u cijelome svijetu. S obama ovim fenomenima izravno su povezana zagađivala iz okoliša, poput potencijalno toksičnih elemenata (PTE). Dva elementa koja izazivaju najveću zabrinutost su arsen (As) i olovo (Pb) u tlu i vodi, bilo da su tamo došli prirodnim putem ili zbog ljudske djelatnosti. Oba su i potencijalno kancerogena. U ovom preglednom radu razmatraju se mehanizmi kojima As i Pb ugrožavaju metaboličke procese i izazivaju oštećenja genoma. Unatoč zabranama i naporima da se ograniči njihovo korištenje, oba su elementa perzistentna u okolišu i predstavljaju rizik za ljudsko zdravlje, zbog čega je potrebno nastaviti s njihovim toksikološkim istraživanjima.

KLJUČNE RIJEČI: arsen trioksid; ljudsko zdravlje; metali; oksidacijski stres; oštećenje DNA; reaktivne kisikove vrste; toksikologija; zakonska regulativa